Zobrazeno 1 - 10
of 77
pro vyhledávání: '"R. L. Capizzi"'
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1202:309-316
Deoxycytidine kinase is a key anabolic enzyme for the activation of ara-C and other antitumor drugs, as well as normal purine and pyrimidine deoxynucleotides. Previously, two forms of the kinase have been identified; deoxycytidine kinase I (70 kDa) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6d38e7b39f9f8a12c7adab70f31172
https://doi.org/10.1016/0167-4838(93)90021-i
https://doi.org/10.1016/0167-4838(93)90021-i
Publikováno v:
Baillière's Clinical Haematology. 4:15-45
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b94406a9f9691914744fe76d70dba7c
https://doi.org/10.1016/s0950-3536(05)80283-5
https://doi.org/10.1016/s0950-3536(05)80283-5
Autor:
R L, Capizzi, W, Oster
Publikováno v:
International journal of hematology. 72(4)
Amifostine (Ethyol), the first broad-spectrum cytoprotectant approved in many countries for clinical use, is an analog of cysteamine and was originally developed by the U.S. Walter Reed Army Institute of Research in the 1950s as a radioprotective age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::55c5ffdf635d5df7eb53118b177d3334
https://pubmed.ncbi.nlm.nih.gov/11197208
https://pubmed.ncbi.nlm.nih.gov/11197208
Autor:
R L, Capizzi
Publikováno v:
Seminars in oncology. 26(2 Suppl 7)
Cisplatin, a heavy metal complex, is one of the most active drugs used in the treatment of a variety of cancers. One of the major limitations to the maximization of its therapeutic potential is nephrotoxicity. Several preclinical studies have shown t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cceb4701ef2551922adb1da84e423b36
https://pubmed.ncbi.nlm.nih.gov/10348264
https://pubmed.ncbi.nlm.nih.gov/10348264
Autor:
R L, Capizzi
Publikováno v:
Seminars in oncology. 26(2 Suppl 7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::036771b1c8e3be3283c7c5e9c338ece5
https://pubmed.ncbi.nlm.nih.gov/10348254
https://pubmed.ncbi.nlm.nih.gov/10348254
Autor:
R L, Capizzi
Publikováno v:
Seminars in oncology. 26(2 Suppl 7)
Administered before cytotoxic chemotherapy or radiation, the aminothiol, amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA), provides broad-spectrum cytoprotection of various normal tissues without attenuati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6e4aeab0614f5abddcae75b0249ecabe
https://pubmed.ncbi.nlm.nih.gov/10348255
https://pubmed.ncbi.nlm.nih.gov/10348255
Autor:
R L, Capizzi
Publikováno v:
Oncology (Williston Park, N.Y.). 13(1)
Amifostine (Ethyol) is an analog of cysteamine that selectively protects normal tissues in multiple organ systems against the toxic effects of radiation and various cytotoxic drugs while preserving the antitumor effects of these therapies. Amifostine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::84ac5d9abfb42a1edcfc3a635a53c062
https://pubmed.ncbi.nlm.nih.gov/10027198
https://pubmed.ncbi.nlm.nih.gov/10027198
Publikováno v:
Seminars in oncology. 23(4 Suppl 8)
The effects of amifostine on paclitaxel-induced tumor growth delay using in vivo human ovarian cancer models were evaluated. In some mouse strains amifostine causes hypothermia and/or vasodilation, leading to increased spleen weight and ascites that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b24eb722fa3d31f663c5bc35009537e6
https://pubmed.ncbi.nlm.nih.gov/8783664
https://pubmed.ncbi.nlm.nih.gov/8783664
Autor:
R A, Fleming, R L, Capizzi, H B, Muss, S, Smith, D J, Fernandes, H, Homesley, B W, Loggie, L, Case, R, Morris, G B, Russell, F, Richards
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 2(7)
We conducted a combined biochemical modulation trial of N-(phosphonacetyl)-L-aspartate (PALA), dipyridamole (DP), and fluorouracil (5-FU) in patients with cancer. Eighty-eight patients with advanced cancer were entered into this Phase I trial. During
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::888f9b44bd3dfea98ea25424c35fbbad
https://pubmed.ncbi.nlm.nih.gov/9816275
https://pubmed.ncbi.nlm.nih.gov/9816275
Publikováno v:
Blood. 86(7)
One of the principal challenges of cancer chemotherapy is the relative inability of most anticancer drugs to distinguish between normal and neoplastic tissues. Consequently, a broad range of toxicities are experienced by patients, especially myelosup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::db8fa683c46bf6bcdce0fd16df1ca498
https://pubmed.ncbi.nlm.nih.gov/7670119
https://pubmed.ncbi.nlm.nih.gov/7670119